Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

14,597 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting hydrogen sulfide as a promising therapeutic strategy for atherosclerosis.
Xu S, Liu Z, Liu P. Xu S, et al. Int J Cardiol. 2014 Mar 15;172(2):313-7. doi: 10.1016/j.ijcard.2014.01.068. Epub 2014 Jan 24. Int J Cardiol. 2014. PMID: 24491853 Review.
Regulated expression of endothelial lipase in atherosclerosis.
Wu X, Huang H, Tang F, Le K, Xu S, Liu P. Wu X, et al. Among authors: xu s. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):233-8. doi: 10.1016/j.mce.2009.11.003. Epub 2009 Nov 18. Mol Cell Endocrinol. 2010. PMID: 19931348
Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway.
Lan T, Shen X, Liu P, Liu W, Xu S, Xie X, Jiang Q, Li W, Huang H. Lan T, et al. Among authors: xu s. Arch Biochem Biophys. 2010 Oct 15;502(2):112-20. doi: 10.1016/j.abb.2010.07.012. Epub 2010 Jul 18. Arch Biochem Biophys. 2010. PMID: 20646989
Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-κB signaling pathway.
Jiang Q, Liu P, Wu X, Liu W, Shen X, Lan T, Xu S, Peng J, Xie X, Huang H. Jiang Q, et al. Among authors: xu s. Mol Cell Endocrinol. 2011 Jan 1;331(1):34-40. doi: 10.1016/j.mce.2010.07.023. Epub 2010 Jul 30. Mol Cell Endocrinol. 2011. PMID: 20674665
Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression.
Tang FT, Cao Y, Wang TQ, Wang LJ, Guo J, Zhou XS, Xu SW, Liu WH, Liu PQ, Huang HQ. Tang FT, et al. Among authors: xu sw. Eur J Pharmacol. 2011 Jan 10;650(1):275-84. doi: 10.1016/j.ejphar.2010.07.038. Epub 2010 Sep 17. Eur J Pharmacol. 2011. PMID: 20854809
Cardiovascular actions and therapeutic potential of tanshinone IIA.
Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. Gao S, et al. Among authors: xu s. Atherosclerosis. 2012 Jan;220(1):3-10. doi: 10.1016/j.atherosclerosis.2011.06.041. Epub 2011 Jun 30. Atherosclerosis. 2012. PMID: 21774934 Review.
Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet.
Xu S, Little PJ, Lan T, Huang Y, Le K, Wu X, Shen X, Huang H, Cai Y, Tang F, Wang H, Liu P. Xu S, et al. Arch Biochem Biophys. 2011 Nov;515(1-2):72-9. doi: 10.1016/j.abb.2011.08.006. Epub 2011 Aug 26. Arch Biochem Biophys. 2011. PMID: 21889487
Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation.
Xu S, Liu Z, Huang Y, Le K, Tang F, Huang H, Ogura S, Little PJ, Shen X, Liu P. Xu S, et al. Transl Res. 2012 Aug;160(2):114-24. doi: 10.1016/j.trsl.2012.01.008. Epub 2012 Feb 2. Transl Res. 2012. PMID: 22677363
LOX-1 in atherosclerosis: biological functions and pharmacological modifiers.
Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P. Xu S, et al. Cell Mol Life Sci. 2013 Aug;70(16):2859-72. doi: 10.1007/s00018-012-1194-z. Epub 2012 Nov 3. Cell Mol Life Sci. 2013. PMID: 23124189 Free PMC article. Review.
Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4.
Zou J, Le K, Xu S, Chen J, Liu Z, Chao X, Geng B, Luo J, Zeng S, Ye J, Liu P. Zou J, et al. Among authors: xu s. Mol Cell Endocrinol. 2013 May 6;370(1-2):103-12. doi: 10.1016/j.mce.2013.03.006. Epub 2013 Mar 18. Mol Cell Endocrinol. 2013. PMID: 23518069
14,597 results
Jump to page
Feedback